Neurotensin is coexpressed, coreleased, and acts together with GLP-1 and PYY in enteroendocrine control of metabolism

Endocrinology

Volumn 157, Issue 1, 2016, Pages 176-194

  Grunddal, Kaare V ^a,b   Ratner, Cecilia F ^a,b   Svendsen, Berit ^a,c   Sommer, Felix ^d   Engelstoft, Maja S ^a,b,e   Madsen, Andreas N ^a,b   Pedersen, Jens ^a,c   Nøhr, Mark K ^a,b   Egerod, Kristoffer L ^a,b   Nawrocki, Andrea R ^f   Kowalski, Timothy ^f   Howard, Andrew D ^f   Poulsen, Steen Seier ^c   Offermanns, Stefan ^g   Bäckhed, Fredrik ^d   Holst, Jens J ^a,c   Holst, Birgitte ^a,b   Schwartz, Thue W ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Department of Pathology   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e DANISH DIABETES ACADEMY   (Denmark)

^f MERCK RESEARCH LABORATORIES   (United States)

^g MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; NEUROPEPTIDE; NEUROTENSIN; PEPTIDE YY; PERTUSSIS TOXIN; PROGLUCAGON; SOMATOSTATIN; BIOLOGICAL MARKER; BOMBESIN; G PROTEIN COUPLED RECEPTOR; GPCR41 PROTEIN, MOUSE; HYBRID PROTEIN; NEUROMEDIN C; PEPTIDE FRAGMENT; PHOTOPROTEIN; RED FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENTEROENDOCRINE CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; IMMUNOHISTOCHEMISTRY; INTESTINE CRYPT; INTESTINE VILLUS; LASER CAPTURE MICRODISSECTION; MALE; METABOLIC REGULATION; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SECRETORY GRANULE; SMALL INTESTINE; STOMACH EMPTYING; TISSUE CULTURE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ILEUM; INTESTINE MUCOSA; METABOLISM; REPORTER GENE; SECRETION (PROCESS); SECRETORY VESICLE; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; BIOMARKERS; BOMBESIN; ENTEROENDOCRINE CELLS; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; GLUCAGON-LIKE PEPTIDE 1; HUMANS; ILEUM; INTESTINAL MUCOSA; LUMINESCENT PROTEINS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROTENSIN; PEPTIDE FRAGMENTS; PEPTIDE YY; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT FUSION PROTEINS; SECRETORY VESICLES; TISSUE CULTURE TECHNIQUES;

EID: 84954482475     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1600     Document Type: Article

References (94)

1. Johnson LR, Ghishan FK, Kaunitz JD, Merchant JL, Said HM, Wood JD. Physiology of the Gastrointestinal Tract. 2012. 5th ed. San Diego, CA: Academic Press Imprint; Elsevier Science, Technology Books.
2. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837.
3. Engelstoft MS, Egerod KL, Holst B, Schwartz TW. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab. 2008;8:447-449.
4. Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol. 2010;6:444-453.
5. Woods SC. The control of food intake: behavioral versus molecular perspectives. Cell Metab. 2009;9:489-498.
6. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843-854.
7. Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012;14:304-314.
8. Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci. 2015;9:92.
9. Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther. 2015;9:1867-1875.
10. Mordes JP, Liu C, Xu S. Medications for weight loss. Curr Opin Endocrinol Diabetes Obes. 2015;22:91-97.
11. Lutz TA, Bueter M. The physiology underlying Roux-en-Y gastric bypass: a status report. Am J Physiol Regul Integr Comp Physiol. 2014;307:R1275-R1291.
12. Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13:983-988.
13. Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity. 2013;21:1093-1103.
14. Sweeney TE, Morton JM. Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature. Best Pract Res Clin Gastroenterol. 2014;28:727-740.
15. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet. 2006;7:349-359.
16. Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM. Targeted ablation of glucose-dependent insulinotropic polypeptideproducing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem. 2008;283:18365-18376.
17. Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev. 1998;78:1087-1108.
18. Rindi G, Leiter AB, Kopin AS, Bordi C, Solcia E. The "normal" endocrine cell of the gut: changing concepts and new evidences. Ann NY Acad Sci. 2004;1014:1-12.
19. Sei Y, Lu X, Liou A, Zhao X, Wank SA. A stem cell marker-expressing subset of enteroendocrine cells resides at the crypt base in the small intestine. Am J Physiol Gastrointest Liver Physiol. 2011;300:G345-G356.
20. Aiken KD, Kisslinger JA, Roth KA. Immunohistochemical studies indicate multiple enteroendocrine cell differentiation pathways in the mouse proximal small intestine. Dev Dyn. 1994;201:63-70.
21. Aiken KD, Roth KA. Temporal differentiation and migration of substance P, serotonin, and secretin immunoreactive enteroendocrine cells in the mouse proximal small intestine. Dev Dyn. 1992;194:303-310.
22. Egerod KL, Engelstoft MS, Grunddal KV, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology. 2012;153:5782-5795.
23. Engelstoft MS, Egerod KL, Lund ML, Schwartz TW. Enteroendocrine cell types revisited. Curr Opin Pharmacol. 2013;13:912-921.
24. Beucher A, Gjernes E, Collin C, et al. The homeodomain-containing transcription factors Arx and Pax4 control enteroendocrine subtype specification in mice. PLoS One. 2012;7:e36449.
25. Habib AM, Richards P, Cairns LS, et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology. 2012;153:3054-3065.
26. Caraway RE, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973;248:17138-17144.
27. Kempadoo KA, Tourino C, Cho SL, et al. Hypothalamic neurotensin projections promote reward by enhancing glutamate transmission in the VTA. J Neurosci. 2013;33:7618-7626.
28. Leinninger GM, Opland DM, Jo YH, et al. Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system and energy balance. Cell Metab. 2011;14:313-323.
29. Opland D, Sutton A, Woodworth H, et al. Loss of neurotensin receptor-1 disrupts the control of the mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity. Mol Metab. 2013;2:423-434.
30. Leeman SE, Carraway RE. Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann NY Acad Sci. 1982;400:1-16.
31. Blackburn AM, Bloom SR, Edwards AV. Pancreatic endocrine responses to exogenous neurotensin in the conscious calf. J Physiol. 1981;314:11-21.
32. Blackburn AM, Bloom SR, Edwards AV. Pancreatic endocrine responses to physiological changes in plasma neurotensin concentration in the calf. J Physiol. 1981;318:407-412.
33. Kaneto A, Kaneko T, Kajinuma H, Kosaka K. Effects of substance P and neurotensin infused intrapancreatically on glucagon and insulin secretion. Endocrinology. 1978;102:393-401.
34. Semple G, Fioravanti B, Pereira G, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem. 2008;51:5172-5175.
35. Wang Y, Liu JJ, Dransfield PJ, et al. Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles. ACS Med Chem Lett. 2013;4:551-555.
36. Henry M, Rodriguez CG, Wright M, et al. Bile acid related effects on energy expenditure; role of TGR5. Keystone Symposium. Diabetes: New Insights Into Mechanism of Disease and Its Treatment. January 27-February 1, 2013; Keystone, CO.
37. Sommer F, Bäckhed F. The gut microbiota engages different signaling pathways to induce Duox2 expression in the ileum and colon epithelium. Mucosal Immunol. 2015;8:372-379.
38. Svendsen B, Pedersen J, Albrechtsen NJ, et al. An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology. 2015;156:847-857.
39. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab. 2008;8:532-539.
40. Nøhr MK, Pedersen MH, Gille A, et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology. 2013;154:3552-3564.
41. Tang C, Ahmed K, Gille A, et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med. 2015;21:173-177.
42. Böttcher G, Alumets J, Håkanson R, Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept. 1986;13:283-291.
43. Cho HJ, Robinson ES, Rivera LR, et al. Glucagon-like peptide 1 and peptide YY are in separate storage organelles in enteroendocrine cells. Cell Tissue Res. 2014;357:63-69.
44. Roberge JN, Brubaker PL. Regulation of intestinal proglucagonderived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology. 1993;133:233-240.
45. Cooke JH, Patterson M, Patel SR, et al. Peripheral and central administration of xenin and neurotensin suppress food intake in rodents. Obesity. 2009;17:1135-1143.
46. Chelikani PK, Haver AC, Reidelberger RD. Comparison of the inhibitory effects of PYY (3-36) and PYY (1-36) on gastric emptying in rats. Am J Physiol Regul IntegrCompPhysiol. 2004;287:R1064-R1070.
47. Kirchner H, Tong J, Tschöp MH, Pfluger PT. Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants. Am J Physiol Endocrinol Metab. 2010;298:E909-E919.
48. Pappas TN, Debas HT, Chang AM, Taylor IL. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroenterology. 1986;91:1386-1389.
49. Roth KA, Hertz JM, Gordon JI. Mapping enteroendocrine cell populations in transgenic mice reveals an unexpected degree of complexity in cellular differentiation within the gastrointestinal tract. J Cell Biol. 1990;110:1791-1801.
50. Rubin DC, Roth KA, Birkenmeier EH, Gordon JI. Epithelial cell differentiation in normal and transgenic mouse intestinal isografts. J Cell Biol. 1991;113:1183-1192.
51. Li HJ, Ray SK, Singh NK, Johnston B, Leiter AB. Basic helix-loophelix transcription factors and enteroendocrine cell differentiation. Diabetes Obes Metab. 2011;13(suppl 1):5-12.
52. May CL, Kaestner KH. Gut endocrine cell development. Mol Cell Endocrinol. 2010;323:70-75.
53. Takeuchi T, Hosaka M. Sorting mechanism of peptide hormones and biogenesis mechanism of secretory granules by secretogranin III, a cholesterol-binding protein, in endocrine cells. Curr Diabetes Rev. 2008;4:31-38.
54. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070-1077.
55. Greeley GH Jr, Hill FL, Spannagel A, Thompson JC. Distribution of peptide YY in the gastrointestinal tract of the rat, dog, and monkey. Regul Pept. 1987;19:365-372.
56. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther. 2009;124:44-56.
57. Schmidt JB, Gregersen NT, Pedersen SD, et al. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab. 2014;306:E1248-E1256.
58. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr. 2010;92:810-817.
59. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY (3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology. 2005;146:3748-3756.
60. Hauge M, Vestmar MA, Husted AS, et al. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol Metab. 2015;4:3-14.
61. Werry TD, Wilkinson GF, Willars GB. Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+. Biochem J. 2003;374:281-296.
62. Schneeberger M, Gomis R, Claret M. Hypothalamic and brainstem neuronal circuits controlling homeostatic energy balance. J Endocrinol. 2014;220:T25-T46.
63. Kessler JP, Beaudet A. Association of neurotensin binding sites with sensory and visceromotor components of the vagus nerve. J Neurosci. 1989;9:466-472.
64. Koda S, Date Y, Murakami N, et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology. 2005;146:2369-2375.
65. Vahl TP, Tauchi M, Durler TS, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology. 2007;148:4965-4973.
66. Bucinskaite V, Tolessa T, Pedersen J, et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil. 2009;21:978-e78.
67. Iwasaki Y, Kakei M, Nakabayashi H, et al. Pancreatic polypeptide and peptide YY3-36 induce Ca2+ signaling in nodose ganglion neurons. Neuropeptides. 2013;47:19-23.
68. Aronin N, Carraway RE, Ferris CF, Hammer RA, Leeman SE. The stability and metabolism of intravenously administered neurotensin in the rat. Peptides. 1982;3:637-642.
69. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585-3596.
70. Holst Pedersen J, Skov Olsen P, Kirkegaard P. Effect of neurotensin and neurotensin fragments on gastric acid secretion in man. Regul Pept. 1986;15:77-86.
71. Mogard MH, Maxwell V, Sytnik B, Walsh JH. Regulation of gastric acid secretion by neurotensin in man. Evidence against a hormonal role. J Clin Invest. 1987;80:1064-1067.
72. Alexander MJ, Leeman SE. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J Comp Neurol. 1998;402:475-500.
73. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7:2294-2300.
74. Gustafson EL, Smith KE, Durkin MM, et al. Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system. Brain Res Mol Brain Res. 1997;46:223-235.
75. Hernandez EJ, Whitcomb DC, Vigna SR, Taylor IL. Saturable binding of circulating peptide YY in the dorsal vagal complex of rats. Am J Physiol. 1994;266:G511-G516.
76. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403:261-280.
77. Chen CH, Rogers RC. Central inhibitory action of peptide YY on gastric motility in rats. Am J Physiol. 1995;269:R787-R792.
78. Chen CH, Stephens RL Jr, Rogers RC. PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC. Neurogastroenterol Motil. 1997;9:109-116.
79. Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA. Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol. 2009;587:4749-4759.
80. Abbott CR, Monteiro M, Small CJ, et al. The inhibitory effects of peripheral administration of peptide YY (3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagalbrainstemhypothalamic pathway. Brain Res. 2005;1044:127-131.
81. Janssen P, Verschueren S, Rotondo A, Tack J. Role of Y (2) receptors in the regulation of gastric tone in rats. Am J Physiol Gastrointest Liver Physiol. 2012;302:G732-G739.
82. Nagell CF, Wettergren A, Ørskov C, Holst JJ. Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol. 2006;41:667-672.
83. Reidelberger R, Haver A, Anders K, Apenteng B. Role of capsaicinsensitive peripheral sensory neurons in anorexic responses to intravenous infusions of cholecystokinin, peptide YY-(3-36), and glucagonlike peptide-1 in rats. Am J Physiol Endocrinol Metab. 2014;307:E619-E629.
84. Kessler JP, Moyse E, Kitabgi P, Vincent JP, Beaudet A. Distribution of neurotensin binding sites in the caudal brainstem of the rat: a light microscopic radioautographic study. Neuroscience. 1987;23:189-198.
85. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology. 1994;107:1848-1855.
86. Béraud-Dufour S, Abderrahmani A, Noel J, et al. Neurotensin is a regulator of insulin secretion in pancreaticβ-cells. Int J Biochem Cell Biol. 2010;42:1681-1688.
87. Dolais-Kitabgi J, Kitabgi P, Brazeau P, Freychet P. Effect of neurotensin on insulin, glucagon, and somatostatin release from isolated pancreatic islets. Endocrinology. 1979;105:256-260.
88. Feurle GE, Müller B, Rix E. Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in rats. Gut. 1987;28(suppl):19-23.
89. Wood JG, Hoang HD, Bussjaeger LJ, Solomon TE. Effect of neurotensin on pancreatic and gastric secretion and growth in rats. Pancreas. 1988;3:332-339.
90. Coppola T, Béraud-Dufour S, Antoine A, Vincent JP, Mazella J. Neurotensin protects pancreatic β cells from apoptosis. Int J Biochem Cell Biol. 2008;40:2296-2302.
91. Boules M, Cusack B, Zhao L, Fauq A, McCormick DJ, Richelson E. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Res. 2000;865:35-44.
92. Feifel D, Goldenberg J, Melendez G, Shilling PD. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology. 2010;58:195-198.
93. Petersen N, Reimann F, Bartfeld S, et al. Generation of L cells in mouse and human small intestine organoids. Diabetes. 2014;63:410-420.
94. Petersen N, Reimann F, Van Es JH, et al. Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest. 2015;125:379-385.